For research use only. Not for therapeutic Use.
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases[1].
GSK-3/CDK5/CDK2-IN-1 inhibits the phosphorylation of cdk5 peptide substrate phosphorylation, with an IC50 of less than about 50 μM[1].
Catalog Number | I044560 |
CAS Number | 395074-72-3 |
Synonyms | N-[1-(3-acetamidocyclobutyl)imidazol-4-yl]-2-naphthalen-2-ylacetamide |
Molecular Formula | C21H22N4O2 |
Purity | ≥95% |
InChI | InChI=1S/C21H22N4O2/c1-14(26)23-18-10-19(11-18)25-12-20(22-13-25)24-21(27)9-15-6-7-16-4-2-3-5-17(16)8-15/h2-8,12-13,18-19H,9-11H2,1H3,(H,23,26)(H,24,27) |
InChIKey | XJRCZTVFSOVAQW-UHFFFAOYSA-N |
SMILES | CC(=O)NC1CC(C1)N2C=C(N=C2)NC(=O)CC3=CC4=CC=CC=C4C=C3 |
Reference | [1]. Ahlijanian MK, et, al. Preparation of acylaminoimidazoles as inhibitors of cdk5, cdk2, and GSK-3. WO2002010141A1. |